Want to see HK:9966 full AI Analyst Report?
9966 Stock Chart & Stats
HK$11.90
-HK$0.05(-1.46%)
At close: 4:00 PM EST
HK$11.90
-HK$0.05(-1.46%)
Day’s Range― - ―
52-Week RangeHK$6.23 - HK$15.75
Previous CloseN/A
Volume1.49M
Average Volume (3M)1.21M
Market Cap
HK$7.87B
Enterprise ValueHK$5.37K
Total Cash (Recent Filing)HK$1.35B
Total Debt (Recent Filing)HK$123.03M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding974,381,700
10 Day Avg. Volume995,025
30 Day Avg. Volume1,208,758
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)4.94
Price to Sales (P/S)15.34
P/FCF Ratio-55.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)HK$313.90M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA gross margin near 77% provides a meaningful economic base for an oncology biotech, because successful products can retain substantial revenue after direct costs. If commercial scale improves, this margin profile could support operating leverage and greater reinvestment in development.
Conservative LeverageVery low leverage gives Alphamab greater financial flexibility than a heavily indebted biotech and limits the burden of interest and mandatory repayment obligations. The sizable equity base provides support for continued development and helps the company absorb operating volatility.
Multiple Monetization RoutesAlphamab’s stated model offers several ways to monetize oncology assets, including internal commercialization, regional rights deals, milestones and royalties. This integrated and partnering approach can broaden potential revenue sources as candidates progress through development and approval.
Bears Say
Sharp Revenue DeclineThe sharp 2025 revenue contraction shows that commercial performance remains volatile rather than steadily scaling. Continued weakness would reduce funds available for research and commercialization, make planning more difficult, and increase reliance on successful product launches or partnerships.
Return To LossesThe return from profitability in 2024 to a sizable 2025 net loss indicates that earnings conversion is not yet dependable. Persistent losses could delay the company’s ability to fund growth internally and make future performance more sensitive to development and commercial execution.
Renewed Cash BurnThe reversal to negative operating and free cash flow signals that the business consumed cash while revenue and earnings weakened. If this pattern persists, Alphamab may face greater funding sensitivity and less flexibility to sustain its oncology development and commercialization programs.
Alphamab Oncology News
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$6.23 and its highest was HK$15.75 in the past 12 months.
What is Alphamab Oncology’s market cap?
Alphamab Oncology’s market cap is HK$7.87B.
When is Alphamab Oncology’s upcoming earnings report date?
Alphamab Oncology’s upcoming earnings report date is Mar 30, 2027 which is in 187 days.
How were Alphamab Oncology’s earnings last quarter?
Alphamab Oncology released its earnings results on Aug 27, 2026. The company reported -HK$0.047 earnings per share for the quarter.
Is Alphamab Oncology overvalued?
According to Wall Street analysts Alphamab Oncology’s price is currently Overvalued.
Does Alphamab Oncology pay dividends?
Alphamab Oncology does not currently pay dividends.
What is Alphamab Oncology’s EPS estimate?
Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alphamab Oncology have?
Alphamab Oncology has 974,381,700 shares outstanding.
What happened to Alphamab Oncology’s price movement after its last earnings report?
Alphamab Oncology reported an EPS of -HK$0.047 in its last earnings report. Following the earnings report the stock price went up 7.806%.
Which hedge fund is a major shareholder of Alphamab Oncology?
Currently, no hedge funds are holding shares in HK:9966
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphamab Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alphamab Oncology
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Technical Analysis
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Shanghai Henlius Biotech, Inc. Class H
―